Guggenheim Reiterates a Buy Rating on AbbVie (ABBV), Sets a PT of $227

AbbVie Inc. (NYSE:ABBV) is one of the best drug stocks to buy right now. In a report released on September 11, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV), setting a price target of $227.00.

AbbVie (ABBV)'s Dividend Track Record: How It Became a Leader in Consistent Dividends

In its fiscal Q2 2025 results, AbbVie Inc. (NYSE:ABBV) reported a diluted EPS of $0.52 on a GAAP basis, reflecting a decrease of 32.5%. Adjusted diluted EPS for the quarter reached $2.97, up 12.1%. Management reported that the results included an “unfavorable impact of $0.42 per share.”

Furthermore, AbbVie Inc. (NYSE:ABBV) delivered net revenues of $15.423 billion in fiscal Q2 2025, up 6.6% on a reported basis or 6.5% on an operational basis.

AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.

While we acknowledge the potential of ABBV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABBV and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.